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Invasive disease caused by Streptococcus pneumoniae and Staphylococcus aureus is 
associated with nasal carriage of these bacteria. Use of a pneumococcal conjugate 
vaccine (PCV) in children altered nasal carriage rates and reduced infections due to S. 
pneumonia. Similar studies demonstrate that there is an inverse correlation between S. 
pneumoniae and S. aureus nasal carriage in children, but this inverse correlation has not 
been extensively investigated adults.  The PCV is now approved for use in adults, a group 
more likely to be colonized with S. aureus.  To investigate the impact of PCV vaccination 
on S. aureus carriage in adults, the clinical evaluation of a multiplex Real Time PCR 
method to simultaneously detect very low levels of S. pneumoniae and S. aureus from the 
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Staphylococcus aureus is a leading causative agent of disease in humans, ranging 
from harmless skin infections to life-threatening systemic infections, and S. aureus is a 
commensal bacteria, colonizing about 30% of the human population (Tong, Davis, 
Eichenberger, Holland, & Fowler, 2015, Wertheim et al., 2005).  Noskin et al. (2005) 
reports the burden of S. aureus on U. S. hospitals to be five times the risk of death, three 
times the length of stay, and three times the total cost: therefore, interventions that 
promote S. aureus colonization in humans may be increasing the burden of S. aureus 
infection. Some studies suggest a causal relationship between widespread use of 
pneumococcal conjugate vaccines (PCV7, PCV13, Prevnar®) and increased carriage 
rates of S. aureus due to the antagonistic relationship between S. pneumoniae and S. 
aureus (Creech, Kernodle, Alsentzer, Wilson, & Edwards, 2005, Spijkerman et al., 2012). 
This paper describes the evaluation of a novel multiplex real-time PCR (RT-PCR) assay 
designed to simultaneously detect S. aureus and S. pneumoniae from nasal samples to 
investigate the theory of in-vivo antagonism between the bacteria. 
As reported by Marchisio, Esposito, and Shito (2002), S. pneumoniae is a 
commensal bacteria found in the nasopharynx of 73.1% of healthy children under two 
years old and 68.9% of healthy children aged 2-5 years. S. pneumoniae is also the leading 
cause of vaccine preventable death in the United States, with children under two years of 
age and adults over 65 being at highest risk for invasive pneumococcal disease (IPD) 
(Moore & Whitney, 2015). In 2001, the Advisory Committee on Immunization Practices 
for the CDC issued a new recommendation that all children aged 2-59 months be 







vaccinations, S. pneumoniae was responsible for 5,000,000 cases of acute otitis media, 
17,000 cases of invasive disease, and 200 deaths annually (Centers for Disease Control 
and Prevention, 2015).  While overall S. pneumoniae carriage rates have remained stable, 
decreases in the invasive serotypes covered by the vaccine have decreased the incidence 
of IPD in children under five years from 100 cases per 100,000 in 1998 to 9 cases per 
100,000 in 2015 (CDC, 2015). 
Long known as the cause of human infections, the epidemiology of S. aureus 
infections shifted in the 1990’s to emphasize healthcare associated infections, especially 
those associated with infective endocarditis, prosthetic device infections and community 
associated skin and soft tissue infections, and the relationship between commensally 
carried S. aureus including methicillin resistant S. aureus (MRSA) and its connection to 
disease. (Tong et al., 2015, Wertheim et al., 2005). Genotyping studies of S. aureus 
suggest a causal relationship between nasal carriage of S. aureus and infection (Wertheim 
et al., 2005).  MRSA was initially isolated in the early 1960’s shortly after the 
introduction of methicillin, and is particularly concerning to public health agencies due to 
its resistance to beta lactam inhibitor antibiotics (David & Daum, 2010). MRSA is now 
recognized in two forms: healthcare-associated MRSA (HA-MRSA) defined by the CDC 
(2015) as MRSA isolated within four calendar days of admission to a healthcare facility, 
or two days after central line placement, and community associated MRSA (CA-MRSA) 
defined by the CDC (2015) as MRSA infection isolated from patients without healthcare 
facility risk factors. The CDC reports that two percent of the U.S. population are nasal 
carriers of MRSA. According to the emerging pathogen report published by the CDC in 







incidence rate of 22.72 in 100,000. The overall incidence of MRSA has decreased by 
over 39% since 2005 driven in large part to health care facilities’ infection control 
practices designed to prevent the spread of MRSA (CDC, 2015; David & Daum, 2010). 
The number of CA-MRSA cases continues to increase (CDC, 2015). 
While the anterior nares serve as reservoirs for both S. aureus and S. pneumoniae, 
the two organisms have an antagonistic relationship (Selva et al., 2009). An in vitro study 
by Selva et al. (2009), suggested that H2O2 production by S. pneumoniae was responsible 
for the lysogenic response by S. aureus. However, Reiss-Mandel and Regev-Yochay 
(2015) suggested that in vivo studies support a host immune mediated response as a 
probable explanation of the seeming competitive nature between the two organisms. Of 
particular note was the inverse correlation the authors reported between S. aureus and S. 
pneumoniae strains that have a pilus, as piliated strains tend to be more virulent. Many of 
these virulent, piliated S. pneumoniae strains are also included in the pneumococcal 
vaccine (Reiss-Mandel & Regev-Yochay, 2015). 
   From 2002 to 2007, within two years of routine PCV administration to children, 
Gerber, Coffin, Smathers, and Zaoutis (2009) reported a 300% increase in MRSA 
infection rates in hospitalized children. It is possible that PCV contributed to the increase 
in MRSA infections due to a shift in balance between these competitive niche bacteria.  
Nasal carriage of either S. pneumoniae or S. aureus has been linked to invasive disease 
from the carried organism (Kluytmans, van Belkum, & Verbrugh, 1997).  Spijkerman et 
al. (2012) reported a higher incidence of S. aureus in nasopharyngeal swabs from 







vaccine, and their parents when compared to samples collected prior to vaccine 
administration.  
In 2011, the CDC expanded the use of conjugate pneumococcal vaccine to 
include all persons over the age of 50 to further reduce the incidence of IPD.  At the time 
of this study, there were no studies comparing the pre- and post-vaccination carriage rates 
of S. aureus and S. pneumoniae among adults to the author’s knowledge.  
Previous studies comparing S. pneumoniae and S. aureus carriage rates were 
performed using culture methods.  Unlike using a culture to detect overt infection, 
cultures to detect carrier status may be unreliable due to growth of complex commensal 
respiratory flora. S. pneumoniae can be especially difficult to distinguish from other 
normal nasopharyngeal flora, such as S. viridans when using traditional culture methods 
(CDC, 2015). Recent studies support RT-PCR methods as having superior sensitivity 
than culture methods.  No commercially available multiplex RT-PCR test to 
simultaneously detect S. pneumoniae and S. aureus from nasal samples was available at 
the time of this study. Here the evaluation of a multiplex RT-PCR assay previously 
designed in the Northern Michigan University Laboratory to detect low levels of S. 
aureus and S. pneumoniae carriage in clinical nasal samples is described (Pierpont, 
2016).  
Methods 
This study was approved by the Institutional Review Board of Northern Michigan 
University to include consenting adults (Appendix A). Volunteer test subjects were given 
a questionnaire (Appendix B) to establish age, gender and race. Additional questions 







morbidities such as cancer, bone marrow or organ transplantation, current infections 
requiring antibiotic treatment, and finally PCV immunization status. 
Repeat sampling from multiple sites is recommended in order to identify transient 
carriers of S. aureus (Wertheim et al., 2005). All volunteer subjects used rayon tipped 
swabs (Copan) to self-collect one sample from each nostril by gently inserting a swab 
into the exterior nares, sweeping upwards and rotating around the circumference of the 
nares prior to removal. 
All swabs were directly plated on 5% sheep’s blood agar (SBA) media (Remel). 
Plates were incubated at 35 to 37°C. Plates were inspected at approximately 24 and 48 
hours for alpha hemolytic colonies suspicious for S. pneumoniae and beta hemolytic 
colonies suspicious for S. aureus. Subcultures of suspicious colonies were plated on 5% 
SBA to ensure culture purity for serological testing. The Oxoid Dryspot Pneumo Kit™ 
was used to positively identify S. pneumoniae. The Remel Staphaurex® test kit was used 
to positively identify colonies suspicious for S. aureus. Isolates that tested positive by 
Staphaurex® were plated to mannitol salt agar (MSA) for confirmation by growth and 
fermenter status. 
After primary plating for culture, swabs were placed in Tryptic Soy Broth (TSB) 
as an enrichment media and incubated overnight at 37°C. Aliquots of the inoculated TSB 
media were frozen pending DNA extraction. Following the QIAamp® DNA Mini Kit 
(Qiagen) instructions, 100 ml of inoculated TSB was used for bacterial DNA extraction. 
Extracted DNA was immediately frozen at -70°C pending RT-PCR analysis. A portion of 
TSB from volunteer samples were reserved for subculture to MSA plates to correlate the 







Additionally, due to the low recovery of S. pneumoniae positive clinical samples by 
culture method, nasal samples that were negative for S. aureus and S.pneumoniae by both 
culture and multiplex RT-PCR were spiked with S. pneumoniae in concentrations ranging 
from 1.53 x 106 copies per microliter through 1.53 x 102 copies per microliter. A nasal 
sample that was positive for S. aureus by culture and nuc positive by multiplex RT-PCR 
was spiked with the same dilutions of S. pneumoniae.  
Genes selected for target analysis were based on PubMed searches of current 
literature. The thermonuclease (nuc) gene was selected as a recommended target region 
to identify S. aureus (Chesneau, Allignet, & El Solh, 1993). A nuc sense 5’-GTTGCT-
TAGTGTTAACTTTAGTTGTA-3’and antisense 3’- TTTAATGTATTTCTTGGA-
CGCTGTAA -5’ primer set previously characterized by Kilic, Muldrew, Tang, and 
Basustaoglu (2009) was used in the multiplex RT-PCR analysis. Repeated testing with 
known S. aureus strains produced amplicons with melting peaks between 78.28°C and 
78.96°C.  The CDC recommends the lytA gene to identify S. pneumoniae. Biosoft Beacon 
Designer software was used to design a primer set, lytA sense 5’- CACGAATAACCA-
ACCAAA -3’ and antisense 3’ –TAGCCAGTGTCATTCTTC- 5’, to detect the lytA gene 
with an amplicon melting peak range of 81.90°C to 82.62°C that showed no cross 
reactivity with the nuc primer set. All primer sequences were analyzed with NCBI Blast 
program to rule out potential cross reactivity with human DNA. The sequences were 
manufactured by IDT (Table 1).  
IDTE buffer was added to equal parts of the lytA and nuc primers to achieve a 5.0 
micro-molar concentration. Each reaction used 3µL molecular grade water, 2µL of the 







LightCycler 96 was used with FastStart Essential Green DNA Master (Roche Applied 
Science). RT-PCR cycling conditions were as follows: initial denaturation at 95°C for 
600 seconds with a ramp rate of 4.4°C per second, followed by 45 cycles of a three step 
amplification including 95°C for 10 seconds with a ramp rate of 4.4°C per second, 62°C 
for 10 seconds with a ramp rate of 2.2°C per second, and 72°C for 10 seconds with a 
ramp rate of 4.4°C per second, followed by a final melting curve comprised of 95°C for 
10 seconds with a  ramp rate of 4.4°C per second, 65°C for 60 seconds with a ramp rate 
of 2.2°C per second, and 97°C for one second with a ramp rate of 0.1°C per second 
(Table 2). 
Results 
A multiplex RT-PCR assay to detect low levels of S. aureus and S. pneumoniae 
was previously developed in our laboratory (Pierpont, 2016). The sensitivity of the assay 
was established by testing serial dilutions of six S. aureus controls and three replicates of 
two S. pneumonia controls with known DNA concentrations. Initial evaluation data 
suggests the assay functions as designed and that it can reliably detect 10 copies of S. 
aureus DNA and 100 copies of S. pneumoniae (Figure 1, Figure 2).  In order to assess the 
performance of the assay in detecting S. aureus and S. pneumoniae in samples that more 
closely mimic clinical conditions, the results of the multiplex real-time assay were 
compared with those obtained by conventional culture and phenotypic identification 
methods using nasal swabs self-collected from 147 adult volunteers at a college campus.  
S. aureus carriage was detected by culture in 41 of 218 samples (22.4 %) and of these 38 
tested positive by multiplex PCR yielding a clinical sensitivity of 92.7% for the PCR 







range was expanded to 77.80°C through 79.20°C based on the melting points of samples 
that were positive for S. aureus by both culture and PCR (Figure 3). The results of the 
remaining volunteer samples were considered positive for S. aureus by PCR if detected 
by quantification cycle (Cq) 35.00 and the amplicon’s melting point was within the 
revised range.  All volunteer samples were evaluated for S. aureus using these criteria. S. 
aureus was detected by multiplex RT-PCR in 177 of the 218 samples (Table 4).  When 
the carriage rate is assessed by both culture and RT-PCR, 33 of 147 volunteers were S. 
aureus positive by culture yielding a carriage rate of 22.4 %, whereas the number of 
volunteers with a positive sample as determined by RT-PCR was 139, a 94.6% carriage 
rate (Table 4). Although studies have shown that PCR methods are more sensitive at 
detecting the presence of low bacterial loads than culture methods, the number of samples 
positive for S. aureus was significantly higher than the currently accepted S. aureus 
carriage rate of 30-50% based on culture so additional testing was warranted to verify the 
findings. (CDC, 2015; Kumar et al., 2008). 
To confirm the unusually high carriage rate of S. aureus, we selected 50 samples 
that were positive by multiplex RT-PCR at a range of Cq values were re-tested by 
uniplex PCR using three separate primer sets. The PCR reactions used a unique nuc 
primer set developed with Biosoft Beacon Designer software, a nuc primer set previously 
characterized by Hoegh et al. (2014), and the nuc primer set previously characterized by 
Kilic et al. (2009), that was used in the multiplex RT-PCR assay. BLAST analysis 
confirmed that each primer set assayed for separate regions of the S. aureus nuc gene and 
the amplicons did not contain overlapping sequences. Samples were considered positive 







corresponded to that generated by positive controls (Figure 2). The uniplex Kilic primer 
set detected S. aureus in 48 of 50 samples, the Hoegh primer set detected S. aureus in 47 
of the 50 samples, and the Biosoft primer set detected S. aureus in 39 of the 50 samples. 
S. aureus was detected in 39 of the 50 samples with all three uniplex primer sets (Table 
5). Amplification was detected at similar Cq values for the majority of samples assayed 
by all three primer sets. Data gathered from the previous evaluation studies suggest the 
Biosoft nuc primers were less efficient, and subsequently less sensitive for S. aureus than 
the Kilic or Hoegh nuc primer sets (data not shown). These findings conservatively 
suggest that at a minimum the S. aureus nuc gene was present in 75% of the volunteer 
samples with positive calls using the multiplex RT-PCR assay. 
The nuc gene is highly conserved in most S. aureus strains and many studies have 
verified its utility in the detection of S. aureus (Kilic et al., 2009; Menzies, 1977). To 
verify that other bacteria commonly carried in the nose were not causing false positive 
results, TSB aliquots from 13 multiplex RT-PCR nuc positive volunteer samples were 
sub-cultured to MSA plates and cultured overnight. S. aureus growth was observed in 
MSA sub-culture from the three volunteer samples, six samples grew non-aureus 
Staphylococcus, and four exhibited no growth after overnight incubation (Table 6). DNA 
extracted from the non-S. aureus culture growth isolated on MSA were all negative for 
the nuc gene with the multiplex RT-PCR assay, suggesting that the multiplex RT-PCR 
positive results were due to the presence of S. aureus.  Collectively these experimental 
results suggest that as many as 76% of the study volunteers may be carriers of S. aureus 







There was insufficient data to evaluate the sensitivity of the multiplex RT-PCR 
assay to detect S. pneumoniae as only five nasal samples obtained from the volunteers 
were positive by culture. Only three of the five culture positive samples were available 
for PCR analysis and of the three, S. pneumoniae was detected in only two. An additional 
seven samples were positive for S. pneumoniae by multiplex RT-PCR that were culture 
negative (Table 7). To further evaluate the detection sensitivity for S. pneumoniae with 
the multiplex RT-PCR assay, two volunteer nasal samples, one that was negative for S. 
pneumoniae and S. aureus by both PCR and culture, and one that was negative for S. 
pneumoniae and positive for S. aureus by culture and PCR, were spiked with S. 
pneumoniae at concentration ranging from 1.53 x 106 copies per microliter through 1.53 
x 102 copies per microliter. S. pneumoniae was detected in the spiked nasal samples 
negative for S. aureus at 1.53 x 106 copies per microliter through 1.53 x 103 copies per 
microliter (Table 8). S. pneumoniae was not detected at 1.53 x 102 copies per microliter. 
No S. pneumoniae was detected in the in any of the S. aureus positive nasal samples that 
were spiked with S. pneumoniae. 
Discussion 
This study was performed to establish the usefulness of a multiplex RT-PCR 
assay to simultaneously detect very low levels of S. aureus and S. pneumoniae from 
enriched nasal cultures by comparing the detection of these bacteria by conventional 
culture and RT-PCR assay. The assay is relatively sensitive for detection of S. aureus; of 
41 samples positive for S. aureus by culture, 38 were positive by multiplex RT-PCR 







acceptable limits per Clinical Laboratory Standards Institute guidelines (2008). Notably, 
S. aureus was detected by multiplex RT-PCR in 139 out of 177 culture negative samples. 
Multiple studies have demonstrated that nucleic acid amplification based methods are 
superior to culture for detection of low level bacterial carriage, especially in 
asymptomatic individuals (Kumar et al., 2008). The unexpectedly high rate of detection 
prompted the performance of follow up experiments to determine the presence of the 
thermonuclease gene and to rule out the presence of a homologous thermonuclease gene 
present in another organism in the nasal microbiome.  Detection of S. aureus at 
comparable Cq values by all three uniplex PCR assays suggest that the thermonuclease 
gene was present in at least 75% of the samples.  Multiplex RT-PCR results were all 
negative from the extracted DNA of non-S. aureus organisms as identified by MSA sub-
culture suggest that the thermonuclease gene detected is specific to S. aureus. The Cq 
values of RT-PCR positive samples were compared to S. aureus detection by culture. In 
28 of 41 culture positive samples, initial multiplex RT-PCR analysis detected S. aureus at 
a Cq ≤ 20.00. As the level of detection for S. aureus control samples was determined to 
be as low as 10 DNA copies by Cq 35.00, samples that tested positive by Cq 35.00 can be 
considered true positives with a reasonable level of assurance. Of the culture positive 
samples, 28 were positive for S. aureus by PCR Cq at or before Cq 20.00. This finding 
suggests that a significantly higher bacterial burden is required for detection by culture 
than is needed for detection by RT-PCR. It also suggests that S. aureus was present at 
levels below culture limits of detection in volunteer samples that tested positive by 







The multiplex RT-PCR assay did not efficiently amplify the lytA gene found in S. 
pneumoniae. Samples were culture positive for S. pneumoniae from three volunteers, 
whereas the multiplex RT-PCR assay was positive for S. pneumoniae in only two of the 
three volunteers. S. pneumoniae was detected in seven volunteer samples that did not 
have culture positive results, however, all of the Cq values for lytA amplification were 
greater than 20.00 and the inability of the assay to detect S. pneumoniae  in samples 
positive for S. aureus suggest an inefficient lytA primer set.   
S. aureus was detected in at least 76% of the volunteers using the novel multiplex 
RT-PCR assay. Contributing factors to such a high rate of detection include sample 
collection from multiple sites to increase the probability of detecting transient carriers. 
This hypothesis is supported by the finding that collecting swabs from both nostrils of the 
study volunteers increased the likelihood that both persistent and transient carriers of S. 
aureus or S. pneumoniae were identified (Senn, Bassett, Nahimana, Zanetti, & Blanc, 
2012). As noted by Kumar et al. (2008) the use of enrichment media also increases 
sensitivity and overall bacterial detection rates in PCR analysis.  
Use of separate swabs to inoculate primary culture plates and TSB enrichment 
media is recommended and the use of a single swab for both may account for the 
multiplex RT-PCR assay having lower than expected sensitivity rates for both S. aureus 
and S. pneumoniae in culture versus multiplex RT-PCR (Sherlock, Dolan, & Humphreys, 
2010). An additional limitation that may have contributed discrepant results was the use 
of non-flocked rayon swabs were used to collect study samples. It has been suggested 







to detect S. pneumoniae because the shorter fibers release organism more readily than the 
longer fibers comprising non-flocked swabs (Dube, Kaba, Whittaker, Zar, & Nicol, 
2013). Finally, a manual method for DNA extraction was used that may be more 
vulnerable to pre-analytical DNA contamination and as noted by van Tongeren, Degener, 
and Harmsen (2011) the efficiency of the QIAamp® DNA Mini Kit (Qiagen) manual 
DNA extraction method used with the nasal samples can be as low as 7.7% compared to 
other extraction methods.   
Conclusions 
Results of the study suggest that the multiplex RT-PCR assay for the detection of 
S. aureus and S. pneumoniae is more sensitive than culture. Despite the higher sensitivity 
of the multiplex RT-PCR assay, results of the study do not support the use of this 
multiplex RT-PCR assay as a screening method for S. aureus and S. pneumoniae carriage 
due to the limited efficiency of the S. pneumoniae primer set in detecting very low levels 
of S. pneumoniae, especially in mixed cultures that contain S. aureus.  
Evidence of S. aureus carriage rates based on RT-PCR analysis appear 
significantly higher than rates previously reported based on culture. To our knowledge, 
published data states that only 30% of the population are permanent carriers of S. aureus 
and an additional 20 to 30% of the population are transient carriers. S. aureus carriage in 
at least 75% of study volunteers on a university campus will be explored more fully in 
future experiments using DNA extracted from frozen enrichment broth aliquots of the 
volunteer samples performed using an efficient, automated method. If repeat analysis 







presence of S. aureus will be confirmed with a Taqman based probe assay or sequencing 
and a novel LAMP assay to detect the nuc gene and possibly additional gene targets 
specific to S. aureus. An investigation of the clinical significance of S. aureus carriage 
density below levels detectable by culture and possible genetic or environmental factors 
that predispose some persons to S. aureus infection associated with commensal carriage 
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Table 1: Primer sequences 
Primers in Multiplex Sequence 
Kilic nuc forward primer 5’-GTTGCTTAGTGTTAACTTTAGTTGTA-3’ 
Kilic nuc reverse primer 3’- TTTAATGTATTTCTTGGACGCTGTAA -5’ 
Biosoft lytA forward primer 5’- CACGAATAACCAACCAAA -3’ 
Biosoft lytA reverse primer 3’- TAGCCAGTGTCATTCTTC - 5’ 
Primers in Uniplex Sequence 
Hoegh nuc forward primer  5’ - GGTTCTGAAGATCCAACA - 3’ 
Hoegh nuc reverse primer 3’ - GTCTGAATGTCATTGGTTG -5’ 
Biosoft nuc forward primer 5′- GGGTTGATACGCCAGAAACG -3′ 









      Table 2: Roche LightCycler 96 settings 
LightCycler Settings 
Setup    
Run Editor    
Detection Format    
Dyes 1: SYBR Green   
Profile    
Programs    
Temp (°C) Ramp (°C/s) Duration (s) Acquisition Mode 
Pre-incubation    
95 4.4 600 None 
3-Step 
amplification 
   
No. of Cycles: 45    
95 4.4 10 None 
62 2.2 10 None 
72 4.4 10 Single 
Melting    
95 4.4 10 None 
65 2.2 60 None 











Table 3: Assay clinical sensitivity for S. aureus detection 
Samples RT-PCR positive (n=177) RT-PCR negative (n=41) 
Culture positive (n=41) 38 3 










Table 4: S. aureus carriage rates by method 
Volunteers Culture positive Multiplex RT-PCR positive 
147 33 139 










Table 5: Uniplex assay result comparison 

















Table 6: MSA sub-culture results 
No growth Non-fermenter (non-aureus 
Staphylococcus) present 
Fermenter (S. aureus pos) 
4 6 3 









Table 7: S. pneumoniae results 
Samples RT-PCR positive (n=9) RT-PCR negative (n=209) 
Culture positive (n=3) 2 1 














Table 8: Results of nasal samples spiked with S. pneumoniae 
S. pneumoniae concentration Tm °C Cq 
1.53 x 106  82.34 21.71 
1.53 x 105 82.38 28.31 
1.53 x 104  82.41 30.96 
1.53 x 103 82.43 34.66 








































































   


































Appendix A: Institutional Review Board Approval Notice 
Memorandum 
 
TO:  Paul Mann, Cathy Bammert, Josh Sharp, Yuba Gautam 
 Clinical Lab Science, Biology  
 
DATE: August 13, 2015 
 
FROM: Brian Cherry, Ph.D. 
 Assistant Provost/IRB Administrator 
 
SUBJECT:IRB Proposal HS15-678 
 IRB Approval Dates:  8/13/2015- 8/13/2016** 
 Proposed Project Dates:  8/1/2015-8/1/2016 
 "Relationship between methicillin-resistant Staphylococcus aureus nasal 
colonization and vaccination with a pneumococcal vaccine in adults" 
 
The Institutional Review Board (IRB) has reviewed your proposal and has given it final 
approval. To maintain permission from the Federal government to use human subjects in 
research, certain reporting processes are required. 
 
A. You must include the statement "Approved by IRB:  Project # HS15-678" on all 
research materials you distribute, as well as on any correspondence concerning this 
project.  
 
B. If a subject suffers an injury during research, or if there is an incident of non-
compliance with IRB policies and procedures, you must take immediate action to assist 
the subject and notify the IRB chair (dereande@nmu.edu) and NMU's IRB administrator 
(bcherry@nmu.edu) within 48 hours. Additionally, you must complete an Unanticipated 
Problem or Adverse Event Form for Research Involving Human Subjects  
 
C. Please remember that informed consent is a process beginning with a description 
of the project and insurance of participant understanding. Informed consent must 
continue throughout the project via a dialogue between the researcher and research 
participant.  
 
D. If you find that modifications of methods or procedures are necessary, you must 
submit a Project Modification Form for Research Involving Human Subjects before 
collecting data. 
 
E. **If you complete your project within 12 months from the date of your approval 
notification, you must submit a Project Completion Form for Research Involving Human 







approval notification, you must submit a Project Renewal Form for Research Involving 
Human Subjects.  You may apply for a one-year project renewal up to four times. 
 
NOTE:  Failure to submit a Project Completion Form or Project Renewal Form within 12 
months from the date of your approval notification will result in a suspension of Human 
Subjects Research privileges for all investigators listed on the application until the form 
is submitted and approved.  
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Appendix B: Volunteer questionnaire 
Questionnaire to find relationship between MRSA and Prevnar Vaccination among 
adults: 
Q1. Age 
o 18-30 years 
o 31-40 years 
o 41 -49 years 
o 50-59 years 
o 60-69 years 







o Hispanic or Latino 
o Black or African American 
o Native American or American Indian 
o Asian or Pacific Islander 
o Other 
Q4. Have you ever had previous frequent skin infections? 
o Yes 
o No 
o Not Sure 
Q5. Have you ever had previous frequent eye, nose, and throat infections? 
o Yes 
o No 
o Not Sure 
Q6. Have you ever been previously diagnosed with S. aureus or MRSA infection? 
o Yes 
o No 
o Not Sure 
Q7. Have you ever been previously diagnosed with S. pneumoniae infection? 
o Yes 
o No 
o Not Sure 




o Not Sure 









o Not Sure 




o Not Sure 
List antibiotics: _ _ _ ______ _ 
Qll. Have you ever taken Pneumococcal conjugate (Prevnar) vaccination? 
o Yes 
o No 
o Not Sure 
Q12. Have you ever recently been prescribed antibiotics? What Type. ______ , 
o Yes 
o No 
o Not Sure 
Q13. I have read the inform consent. I am willing to participate in this study and give 
consent for Nasal Swab. 
 
 
































15001 R + -        33.91  -  -  
15003 R + -        34.01   -  -  
15003 L + -        34.81   -   - 
15004 L + -        34.74   -   - 
15004 R + -        36.85   -   - 
15005 R + -        15.81   -   - 
15005 L - -        -       - + 
15006 L + -        33.60   - + 
15008 R + -        32.28   -   - 
15008 L - -        -       -   - 
15009 L + -        34.12   -   - 
15009 R + -        35.38   -   - 
15010 R - -            -   - 
15010 L + -        35.83   -   - 
15011 R - -        31.68   -   - 
15011 L + -        34.64   -   - 
15012 R + -        18.39   -   - 
15012 L + -        19.76   -   - 
15013 L + -        32.74   -   - 
15013 R + -        34.08   -   - 
15014 L + -        16.89   -   - 
15014 R + -        19.49   - + 
15015 L + -        15.64   -   - 
15015 R + -        16.19   -   - 
15016 R + -        30.86   -   - 
15016 L + -        30.95   -   - 
15017 R + -        32.47   -   - 
15017 L + -        12.75   - + 
15018 L + -        33.22   -   - 
15018 R - -        33.45   -   - 
15019 L + -        14.47   - + 
15019 R + -        14.59   - + 
15020 R + -        13.40   - + 
15020 L + -        13.60   - + 
15021 R + -        32.71   -   - 


















15022 L + -        31.87  -   - 
15023 R + -        32.77  -   - 
15024 R + -        30.40  -   - 
15024 L + -        36.06  -   - 
15025 L + -        33.15  -   - 
15025 R + -        32.35  - + 
15026 R + -        32.93  - + 
15026 L + -        35.37  - + 
15027 L + -        34.49  -   - 
15027 R + -        36.26  -   - 
15028 L + -        33.81  -   - 
15028 R + -        35.24  -   - 
15029 L + -        32.86  -   - 
15029 R + -        34.70  -   - 
15031 L + -        17.27  - + 
15031 R + -        14.20  -   - 
15032 R + -        33.87  -   - 
15032 L + -        35.63  - + 
15033 R - -        29.31  -   - 
15033 L + -        32.58  -   - 
15034 L + -        33.54  -   - 
15034 R + -        34.24  -   - 
15035 L + -        29.50  -   - 
15035 R + -        30.55  -   - 
15036 L + -        33.79  -   - 
15036 R + -        34.23  -   - 
15037 L + -        15.93  - + 
15037 R + -        16.29  - + 
15038 R + -        14.98  -   - 
15039 R + -        16.48  - + 
15039 L + -        31.52  - + 
15040 R + -        18.14  -   - 
15040 L + -        32.00  -   - 
15041 R + -        33.62  -   - 
15041 L + -        35.60  -   - 
15042 R + -        33.60  -   - 


















15044 L - + 33.20 +   - 
15045 R - + 30.44 -    - 
15045 L + -        32.06  -   - 
15046 L + -        27.12  -   - 
15046 R + -        29.68  -   - 
15047 L - + 30.22 +   - 
15047 R + -        32.83  -   - 
15048 R + -        33.97  -   - 
15048 L + -        35.83  -   - 
15049 L + -        13.49  - + 
15049 R + -        15.25  - + 
15050 R - + 34.24  -   - 
15050 L + -        34.91  -   - 
15051 L + -        32.52  -   - 
15051 R + -        35.72  -   - 
15052 L + -        35.74  -   - 
15052 R + -        29.87  -   - 
15053 L + -        33.26  -   - 
15053 R + -        35.28  -   - 
15054 L + -        31.39  -   - 
15054 R - + 33.85  -   - 
15055 L + -        32.85  -   - 
15055 R + -        36.01  -   - 
15056 L + -        33.70  -   - 
15057 R + -        14.09  - + 
15057 L + -        16.97  - + 
15058 L + -        26.85  -   - 
15059 R + -        30.91  -   - 
15059 L + -        33.37  -   - 
15060 L + -        32.40  -   - 
15060 R + -        33.93  -   - 
15061 L + -        15.14  - + 
15061 R + -        15.39  - + 
15062 R + -        15.03  -   - 
15062 L + -        16.00  -   - 
15063 R + -        27.66  -   - 


















15064 R + -        31.28  -   - 
15064 L + -        33.06  -   - 
15065 R + -        21.81  -   - 
15065 L + -        33.23  -   - 
15066 R + -        33.91  -   - 
15066 L + -        36.17   -   - 
15068 L + -        31.56   -   - 
15068 R + -        33.32   -   - 
15069 L + -        33.49   -   - 
15069 R - -        35.12  -    - 
15071 L + -        13.68   -   - 
15072 R + -        32.77   -   - 
15073 L + -        30.46   -   - 
15074 5L + -        34.06   -   - 
15074 R + -        34.33   -   - 
15074 L - -        -       -   - 
15075 L - -        36.11   -   - 
15076 L + -        27.69   -   - 
15076 R + -        31.52   -   - 
15077 R + -        31.16   -   - 
15077 L + -        35.19 +   - 
15078 R + -        32.35   -   - 
15078 L + -        34.90   -   - 
15079 L + -        36.56   -   - 
15079 R - -        -       -   - 
15080 L + -        31.48   -   - 
15080 R - -        -       -   - 
15082 R + -        30.76   -    - 
15082 L + -        32.19   - + 
15083 L + -        19.02   -  -  
15084 L + -        31.25   -   - 
15085 L + -        29.66   -   - 
15087 L + -        29.00   -   - 
15088 L + -        10.87   -   - 
15090 L - + 28.24   -   - 
15099 L + -        17.03   -   - 


















15100 L + -        35.95   -   - 
15100 R - -        -       -   - 
15101 L + -        29.48   -   - 
15101 R + -        36.21   -   - 
15102 L + -        28.21   -   - 
15102 R + -        35.77   -   - 
15103 L + -        28.62   -   - 
15103 R + -        34.93  -   -  
15104 L + -        28.95   -   - 
15104 R + -        35.37  -    - 
15106 L + -        12.86   -   - 
15107 L + -        12.85   -   - 
15108 L + -        13.16   -   - 
15109 L + -        27.21   -   - 
15111 L + -        13.60   -   - 
15112 L + -        28.13   -   - 
15113 L + -        27.65   -   - 
15115 L + -        26.22   -   - 
15117 L + -        29.12   -   - 
15118 L + -        27.65   -   - 
15119 L + -        26.09   - + 
15120 L + -        27.52   -   - 
15123 L + -        11.08   - + 
15124 L + -        24.21   -   - 
15125 L + -        10.40   - + 
15126 L + -        9.93   - + 
15127 L + -        28.31   -   - 
15128 L + -        25.85   -   - 
15129 L + -        10.96   - + 
15130 L + -        13.41   - + 
15131 L + -        23.62   - + 
15132 L + -        23.99   -   - 
15133 L + -        25.63   -   - 
15150 L + -        15.21   - + 
15151 L + -        28.84   -   - 
15152 L - + 28.66   -   - 


















15154 L + -        13.54   - + 
15155 L + -        28.12   -  -  
15156 L + -        30.87  -    - 
15157 L + -        11.95   - + 
15158 L + -        28.76   -   - 
15159 L + -        26.70   -   - 
15160 L + -        14.57   -   - 
15161 L + -        29.27   -   - 
15162 L + -        26.76   -   - 
15163 L + -        12.77  -    - 
15164 L + -        29.09   -   - 
15165 L + -        28.15   -   - 
15166 L + -        28.09   -   - 
15167 L + -        13.43   - + 
15169 L + -        13.30   - + 
15170 L + -        29.15   -   - 
15171 L + + 26.49   -  -  
15172 L + -        11.60   - + 
15173 L + -        29.68   -   - 
15174 L + -        14.07   - + 
15175 L + -        28.70   -   - 
15176 L + -        13.35   - + 
15177 L + -        28.72   -   - 
15178 L + -        12.82   - + 
15179 L + -        26.74   -   - 
15180 L + -        28.76   -   - 
15181 L + + 29.44   -   - 
15182 L + -        29.56   -   - 
15183 L + -        28.97   -   - 
15184 L - -        -       -   - 
15185 L + -        29.19   -   - 
15186 L + -        26.57   -   - 









Appendix D: Uniplex primer evaluation of nuc positive multiplex samples 
SID Nostril Multiplex Cq Kilic nuc Cq Hoegh nuc Cq Biosoft nuc Cq 
15126 L 9.93 10.38 11.24 21.43 
15125 L 10.40 11.97 11.56 10.62 
15088 L 10.87 11.39 12.11 11.69 
15129 L 10.96 11.14 12.37 11.80 
15123 L 11.08 12.87 12.11 11.50 
15172 L 11.60 12.12 12.75 12.27 
15157 L 11.95 12.70 12.85 12.24 
15163 L 12.77 13.36 13.68 15.37 
15178 L 12.82 13.15 13.88 12.90 
15107 L 12.85 13.29 13.64 12.43 
15107 L 12.85 14.00 14.13 13.54 
15106 L 12.86 13.31 13.96 16.13 
15108 L 13.16 13.64 14.57 14.16 
15169 L 13.30 14.41 14.89 14.97 
15176 L 13.35 13.43 14.22 16.72 
15130 L 13.41 13.13 14.00 13.86 
15167 L 13.43 14.14 14.08 13.12 
15154 L 13.54 13.79 14.77 14.00 
15111 L 13.60 13.58 14.28 13.65 
15174 L 14.07 14.27 15.09 14.41 
15019 L 14.47 35.68 35.67 - 
15160 L 14.57 14.83 15.48 17.95 
15038 R 14.98 15.51 16.28 19.94 
15150 L 15.21 32.60 32.25 33.27 
15040 R 18.14 18.21 18.73 18.26 
15012 L 18.39 20.04 20.32 - 
15083 L 19.02 19.78 19.87 19.95 
15132 L 23.99 25.04 25.36 26.10 
15171 L 26.49 27.73 27.46 26.48 
15186 L 26.57 26.22 27.04 27.84 
15179 L 26.74 27.70 28.96 26.06 
15162 L 26.76 27.64 27.76 30.44 
15120 L 27.15 28.60 29.16 - 
15109 L 27.21 28.36 28.00 26.48 
15118 L 27.65 28.25 28.52 27.14 
15155 L 28.12 28.94 28.29 28.10 
15112 L 28.13 29.02 28.56 - 
15102 L 28.21 29.13 28.54 28.10 
15087 L 29.00 28.66 29.91 - 
15164 L 29.09 29.60 29.45 29.35 







SID Nostril Multiplex Cq Kilic nuc Cq Hoegh nuc Cq Biosoft nuc Cq 
15161 L 29.27 28.04 27.89 28.23 
15101 L 29.48 30.29 29.43 29.75 
15173 L 29.68 30.11 29.24 28.73 
15077 L 31.16 35.56 35.93 - 
15084 L 31.25 31.53 - 30.08 
15054 R 31.39 34.14 32.29 - 
15080 L 31.48 31.61 31.91 - 









Appendix E: MSA sub-culture results 
SID 
Initial sample results MSA Sub-culture results 
Nostril 
TM1 
(°C) Cq    Culture result MSA sub-culture RT-PCR 
15150 L 78.42 15.21 S. aureus pos S. aureus  
15151 L 78.62 28.84  S. aureus neg non-aureus Staph. negative 
15159 L 79.09 26.70  S. aureus neg no growth   
15160 L 78.27 14.57  S. aureus neg S. aureus  
15163 L 78.51 12.77  S. aureus neg S. aureus   
15166 L 78.58 28.09  S. aureus neg no growth   
15175 L 78.60 28.70  S. aureus neg no growth   
15180 L 78.69 28.76  S. aureus neg non-aureus Staph. negative 
15181 L 78.26 29.44  S. aureus neg non-aureus Staph. negative 
15182 L 78.49 29.56  S. aureus neg no growth   
15183 L 78.79 28.97  S. aureus neg non-aureus Staph. negative 
15185 L 78.56 29.19  S. aureus neg non-aureus Staph. negative 
15186 L 78.52 26.57  S. aureus neg non-aureus Staph. negative 
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